AG
CLSD

Advisor Group’s Clearside Biomedical CLSD Stock Holding History

Advisor Group’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Buy
+17
New +$357 ﹤0.01% 5113

Other funds holding CLSD

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Advisor Group's CLSD Position: Q4 2019 in Review

Advisor Group opened a new position in Clearside Biomedical (CLSD) in Q4 2019: 17 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #5113 among its holdings.

47 funds tracked by Wall St. Rank hold CLSD as of Q4 2019.

  • Advisor Group held 17 shares of Clearside Biomedical worth $1K as of Q4 2019.
  • Clearside Biomedical was a new Advisor Group position in Q4 2019.
  • Clearside Biomedical made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5113 holding.
  • 47 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.